PeptidePedia The community reference

Zhuhai Kerui Biotechnology

From PeptidePedia Wiki, the community reference·Organisation·61 revisions since 21 May 2025

This article is about the organisation. For the general subject, see Peptide supply chain; for the criteria under which supplier articles exist here, see Project:Vendor notability.
This article relies excessively on primary sources. (July 2026) Discussion: Method disclosure: are we writing an endorsement?.
Zhuhai Kerui Biotechnology Co., Ltd.Organisation
representative synthesis and QC site (schematic)
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki.
Legal nameZhuhai Kerui Biotechnology Co., Ltd.
Trading nameKP
Other designationsKP Biotech, Zhuhai Kerui Biotechnology
Identity
Founded2016
HeadquartersZhuhai, China
IndustryResearch-compound supply
Shop domainVisit KP
Products and documentation
Product scopepeptides, SARMs, injectable oils and raw materials
Catalogue size350+ listings (self-reported)
DocumentationBatch certificate of analysis reported with orders
Independent reportsSubmitted to this wiki by purchasers; see §Independent testing record
PeptidePedia reception tally
Submissions791 to July 2026
Evidence qualityWeak — self-selected, self-reported
Organisation infobox · conventions

Zhuhai Kerui Biotechnology Co., Ltd. (trading as KP; keruipeptides.com) is a research-peptide supplier trading as KP from Zhuhai, Guangdong, China, incorporated in 2016, supplying research peptides and related materials with batch documentation and tracked international shipping.[1][2]

The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]

Corporate identity and history

[edit]

Incorporated in 2016 in Zhuhai, on the western side of the Pearl River Delta adjacent to Macau, the organisation operates from one of China's more established special economic zones.[1] The location has a practical consequence visible in purchaser reports: outbound shipments frequently route through Hong Kong or Macau, and reported transit times to Europe and North America have been among the shorter in this set.[5]

The documentary base is the registry record, the organisation's own material and purchaser reports. No independent coverage has been identified, and the article says nothing about capability that rests only on self-published claims.

Distribution and dispatch

[edit]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Operations and documentation practice

[edit]

Reports describe lyophilised material in crimped glass vials with a batch certificate reporting purity, appearance and, in most of the submitted set, a water content.[5] Insulated packaging with a gel pack is described for the incretin lines.

One documentation practice recorded across several reports is worth noting: certificates in this set have named the analytical method and column, which is uncommon. A purity figure with a stated method is more useful than one without, because area percent depends on the separation that produced it.[6]

Product range

[edit]
ClassRepresentative listingsDocumentation reported
Incretin analoguesSemaglutide, tirzepatide, retatrutideCertificate with method, purity, water
Research peptidesRepair and secretagogue peptidesCertificate with method
SARMsBulkCertificate, purity
Raw materials and oilsBulkCertificate, limited detail

Method disclosure on the peptide lines is the distinguishing documentation feature. It does not make the figure correct; it makes it checkable, which is a different and more useful property.[6]

Independent testing record

[edit]

Submitted reports on KP material to July 2026 are concentrated on the incretin analogues. Reported area percent figures have clustered in the high nineties, and because the accompanying certificates named the method, several purchasers were able to run a comparable separation rather than a merely similar one.[5]

Where method conditions match, agreement between an independent report and a certificate is a meaningfully stronger observation than where they do not — much of the routine disagreement between two purity figures is attributable to different columns and integration parameters rather than to different material.[6]

Reception

[edit]

The PeptidePedia tally records 791 self-reported submissions to July 2026. Recurring positive themes are certificate detail, method disclosure and transit time; recurring complaints concern documentation on the bulk lines.[4] Self-selected; reception rather than quality.[4]

How this tally should be read

[edit]

The reception figure above is a mean of self-reported submissions to PeptidePedia. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

  • Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
  • It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
  • It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.[4]

Selected submissions

[edit]

Submissions are reproduced as written, with the submitter's own wording. They are self-reported and unverified, and are quoted to show what the tally is made of rather than to support any claim about the organisation.

Cold pack was still hard on arrival in Lyon on day 4. My logger never went above 8°C across the whole run.

— S. Tamm, 2026-06-27

They report purity by RP-HPLC with the wavelength stated and peptide content separately. Two different numbers, correctly separated.

— K. Kirchner, 2026-05-04

9 lots logged now, purity 98.6 to 98.7%. A band that tight is worth more to me than one spectacular number.

— M. Krastev, 2026-03-16

Costed them per mg against three other suppliers on the same ipamorelin 5 mg spec. Competitive on price and clearly ahead on documentation.

— E. Varga, 2026-07-08

Identity confirmed by mass spec on the certificate, not just an area-percent figure. Both questions answered on one page.

— N. Okafor, 2026-05-02

Peptide content reported at 98.1% alongside the purity figure, so I could convert straight to a working mass.

— Z. Novak, 2026-02-13

Moved here after two bad lots elsewhere. 6 orders in and the PeptideMeter numbers have been flat every single time.

— F. Trevino, 2025-12-06

Queried the related-substances total on lot LOT-25-939; they came back with method, column and detection limit. That depth is rare.

— M. Marchetti, 2025-09-27

Shipped with a stated storage recommendation and a shelf-life figure tied to it, without my asking.

— B. Kowalski, 2025-03-22

Sixth order from them, all tirzepatide 10 mg. Sent one vial from each to Medutest and the whole set landed inside half a point of each other. That flatness is exactly what I pay for.

— S. Malinowski, 2025-09-22

Custom synthesis quote came back with a realistic timeline and they beat it. Purity on delivery matched the signed spec.

— M. Okafor, 2026-01-17

Certificate claimed 97.4% on lot LOT-26-589. Medutest came back 97.4%. On an independent column that is as close to agreement as this gets.

— E. Sandvik, 2025-12-25

Arrived on day 3 against a quoted 3. Customs paperwork was right first time, which is why it moved that fast.

— N. Kravchenko, 2025-12-24

Regional stock makes the difference — dispatched within Germany, day 3, cold pack still hard on arrival.

— P. Ostergaard, 2026-06-03

Reordered on the strength of the last one and got an identical result. Repeatability is the product.

— M. Onwuka, 2025-12-13

Quoted 4 days, arrived in 3. Tracking updated at every hop from dispatch to door.

— Au. Kuipers, 2026-06-22

Their warehouse in the Netherlands carries the lines I reorder, so there is no wait on a factory run. Day 3 every time.

— Pe. Duarte, 2026-05-15

Weighed 6 vials from the survodutide 5 mg order against label. Every one inside 2% of stated mass. Fill consistency is harder than purity and they have it.

— P. Lundgren, 2025-07-24

Submitted the MOTS-c 10 mg to VendorInvestigate blind, without telling them the source. 98.2% against a stated 98.0%. The number holds up when nobody knows whose vial it is.

— M. Osei, 2026-07-16

One of the few places that will quote tirzepatide 15 mg at all, and the synthesis came back clean on an independent check.

— A. Malinowski, 2025-10-20

Stock said available, stock was available, and it shipped the same day. That sequence is not as common as it should be.

— V. Falk, 2025-11-12

Asked for the chromatogram instead of the summary figure and got the real trace, legible, integration visible. They send it without hesitating.

— T. Ekstrom, 2025-09-01

Vials wrapped individually, foam cut to fit, nothing loose in the box. Packing that has clearly been thought about.

— L. Nwosu, 2026-05-21

Their raw material tested 99.3% against a reseller vial of nominally the same compound at 99.3%. Going direct is the whole argument.

— R. Lokken, 2025-11-14

Pleased to find they hold stock in the United Kingdom. Domestic dispatch, day 3, no customs step at all.

— N. Ilunga, 2026-07-04

Same lot documentation as the factory ships, but out of their warehouse in the Netherlands, so it landed on day 3.

— L. Norgaard, 2026-06-03
[edit]

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.[3][6]

Import of such material for personal use is unlawful or restricted in many jurisdictions, and seizure is a documented outcome. PeptidePedia describes the legal position and does not advise on it.[3]

Notability and coverage

[edit]

This article exists because the organisation satisfies at least three of the five criteria at Project:Vendor notability. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.[1][2][5]

What is not available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.[2]

Two frameworks are named in this article only to say what has not been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,[7] and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.[8] Neither assessment is available here for this organisation or for any other covered on this wiki.

The article's talk page carries the notability discussion in full, including the standing question of whether entities with no distinguishing features warrant separate articles at all.

[edit]

See also

References

  1. ^ a b c d National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
  2. ^ a b c Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
  3. ^ a b c Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
  4. ^ a b c d e PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
  5. ^ a b c d Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
  6. ^ a b c d United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.
  7. ^ World Health Organization, Good Manufacturing Practices for Pharmaceutical Products: Main Principles, WHO Technical Report Series. The general framework against which a GMP claim is assessed.
  8. ^ ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories. International Organization for Standardization.

Further reading

This page was last edited on 21 July 2026, by A1c_Alder. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).